期刊
HAMOSTASEOLOGIE
卷 41, 期 6, 页码 433-442出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1661-0020
关键词
inflammation; atherosclerosis; strategies
类别
资金
- Austrian Science Fund (FWF) [P-33874-B]
- German Research Foundation (DFG) [ZI 743/7-1, 8-1]
Atherosclerosis, a chronic inflammatory disease triggered by inflammation, can be effectively reduced in terms of cardiovascular events and mortality through anti-inflammatory interventions. Managing risk factors plays a crucial role in attenuating and preventing atherosclerosis and its complications. Promising therapeutic approaches include traditional anti-inflammatory drugs, specific immunomodulation, and vaccination development against atherosclerotic disease.
Atherosclerotic vascular disease and its related complications are the major cause of mortality in Western societies. Atherosclerosis is a chronic inflammatory disease of the arterial wall triggered by traditional and nontraditional risk factors and mediated by inflammatory and immune responses. Recent clinical trials provided compelling evidence corroborating that atherosclerosis is an inflammatory disease and demonstrated efficacy of anti-inflammatory interventions in reducing cardiovascular events and mortality. Traditional risk factors drive vascular inflammation, further justifying the instrumental role of intensified risk factor management in attenuating and preventing atherosclerotic disease and complications. Promising therapeutic approaches specifically related to inhibition of inflammation span traditional anti-inflammatory drugs, specific immunomodulation, and development of vaccination against atherosclerotic disease. Here, we review the inflammatory component in atherogenesis, the available evidence from clinical trials evaluating efficacy of therapeutic anti-inflammatory interventions in patients with high cardiovascular risk, and discuss potential future targets for anti-inflammatory or immune modulatory treatment in atherosclerotic cardiovascular disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据